Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors

NCT01202032 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma
Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed

Interventions

DRUG: Association of Bevacizumab (BVC)+ Pazopanib (PZP)

Sponsor

Centre Leon Berard